AURA Stock News & Analysis | Latest Updates

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:AURA) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET.

September 3, 2025Investor Event

AURA News

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aura Announces Exercise of the Underwriters’ Option to Purchase Additional Shares

HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22

JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target

Aura Biosciences Prices $75M Underwritten Public Offering Of 11,735,565 Shares And Accompanying Warrants Of $4.90/Share

Aura Biosciences Has Launched An Underwritten Public Offering Of Shares And Accompanying Warrants, Details Undisclosed

As Of March 31, 2025, Aura Biosciences Had Cash And Cash Equivalents And Marketable Securities Of $128M, Sufficient To Fund Its Operations Into 2H Of 2026

Aura Biosciences Q1 2025 EPS $(0.55) Misses $(0.48) Estimate

Citizens Capital Markets Maintains Market Outperform on Aura Biosciences, Lowers Price Target to $19

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $25

Aura Biosciences Expects Cash Position To Support Operations Into 2H 2026

Aura Biosciences FY24 EPS $(1.75) Up From $(1.93) YoY

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target

Aura Biosciences Announced Data From A Completed Phase 1 Window Of Opportunity Trial Of Bel-sar (AU-011) In Patients With Non-Muscle-Invasive Bladder Cancer

Aura Biosciences To Present New Phase 1 Data On Bel-Sar For Non-Muscle Invasive Bladder Cancer In Late-Breaking Session At 40th EAU Congress

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target